These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
556 related items for PubMed ID: 20353997
21. [Proliferative signal transmission mediated by EpoR in leukemic cell lines]. Fan H, Kanji S, Zhai M. Zhonghua Xue Ye Xue Za Zhi; 2000 Jun; 21(6):294-7. PubMed ID: 11876995 [Abstract] [Full Text] [Related]
22. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Oncogene; 2010 Sep 02; 29(35):4947-58. PubMed ID: 20562913 [Abstract] [Full Text] [Related]
23. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells. Mut M, Lule S, Demir O, Kurnaz IA, Vural I. Int J Biochem Cell Biol; 2012 Feb 02; 44(2):302-10. PubMed ID: 22085529 [Abstract] [Full Text] [Related]
26. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha. Lam L, Hu X, Aktary Z, Andrews DW, Pasdar M. Breast Cancer Res Treat; 2009 Dec 02; 118(3):605-21. PubMed ID: 19002577 [Abstract] [Full Text] [Related]
34. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y. Breast Cancer Res Treat; 2012 Dec 02; 136(3):739-48. PubMed ID: 23117856 [Abstract] [Full Text] [Related]
35. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. Hamadmad SN, Hohl RJ. J Pharmacol Exp Ther; 2008 Mar 02; 324(3):1227-33. PubMed ID: 18079357 [Abstract] [Full Text] [Related]
36. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. Um M, Lodish HF. J Biol Chem; 2006 Mar 03; 281(9):5648-56. PubMed ID: 16407271 [Abstract] [Full Text] [Related]
37. Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Sheriff S, Ali M, Yahya A, Haider KH, Balasubramaniam A, Amlal H. Mol Cancer Res; 2010 Apr 03; 8(4):604-14. PubMed ID: 20332211 [Abstract] [Full Text] [Related]
38. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation. Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, Neumann D, Rönnstrand L, Påhlman S. Biochem Biophys Res Commun; 2014 Feb 28; 445(1):163-9. PubMed ID: 24502950 [Abstract] [Full Text] [Related]
40. No erythropoietin-induced growth is observed in non-small cell lung cancer cells. Frille A, Leithner K, Olschewski A, Olschewski H, Wohlkönig C, Hrzenjak A. Int J Oncol; 2018 Feb 28; 52(2):518-526. PubMed ID: 29345289 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]